F-1/A: Empro Group Inc. Files for U.S. IPO, Aiming for Nasdaq Listing

Empro Group Inc., a Cayman Islands-based company, has filed an amended registration statement for its initial public offering, seeking to list its ordinary shares on the Nasdaq Capital Market.

Summary

• Empro Group Inc., incorporated in the Cayman Islands, is planning an initial public offering of its ordinary shares.
• The company intends to list its shares on the Nasdaq Capital Market under the ticker symbol EMPG.
• The IPO is being conducted on a firm commitment basis, with underwriters obligated to purchase all shares if any are taken.
• The company's business is primarily conducted through its Malaysian subsidiary, EMP Solution Sdn. Bhd., which operates in the beauty and healthcare sectors.
• Empro's revenue for the fiscal year ended December 31, 2023, was approximately $3.70 million, a decrease from $10.82 million in 2022, due to reduced sales of medical masks and COVID-19 test kits.
• For the six months ended June 30, 2024, total revenue was approximately $1.70 million, with a net loss of approximately $0.28 million.
• The company's flagship products include triangular eyebrow pencils and surgical face masks with patented Aerofit technology.
• Empro distributes its products through various channels, including its own retail outlets, major retailers like Watsons and Sasa, and online platforms such as Shopee and Lazada.
• The company is an emerging growth company and will be subject to reduced public company reporting requirements.
• The company is controlled by its founder, Prof. Dr. Yeoh Chee Wei, who is expected to beneficially own a majority of the outstanding ordinary shares after the offering.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a long history and is expanding into new markets, it also experienced a significant revenue decline and a net loss in the past year. The company is also subject to various risks and challenges. The sentiment is neutral to slightly negative.

Positives

• The company has a rich brand history spanning over 19 years.
• The company has a track record of delivering safe, efficacious, and innovative beauty and healthcare products.
• The company has received numerous accolades and awards for its contributions to the beauty and healthcare industry.
• The company has developed strong relationships with partners, regulators, and government agencies.
• The company has a robust and experienced management team.
• The company is expanding its product offerings and developing new products, such as the Premio and Mios brands and the SpaceLift skincare product.
• The company is expanding into new markets and territories within ASEAN and Europe.
• The company is investing in new technologies.

Negatives

• The company experienced a significant decrease in revenue in 2023 due to reduced demand for healthcare products.
• The company experienced a net loss of approximately $0.32 million in 2023.
• The company relies on a limited number of ODM/OEM and packaging supply partners.
• The company is subject to complex and evolving product safety laws, regulations, and standards.
• The company may be subject to export and import control laws and regulations.
• The company is subject to fluctuations in exchange rates in the MYR.
• The company may be subject to infringement claims of intellectual property rights or other rights of third parties.
• The company is controlled by a single shareholder, whose interest in the business may be different than yours.

Risks

• The company operates in a dynamic healthcare and beauty industry and has a limited operating history.
• The healthcare and beauty industry are highly competitive.
• The company's success is dependent on the continued popularity of its products and its ability to anticipate and respond to changes in industry trends and consumer preferences.
• The company's total revenue decreased considerably during the 2023 fiscal year due to a marked reduction in COVID-19 cases.
• The company's new product introductions may not be as successful as anticipated.
• The company relies on a limited number of ODM/OEM and packaging supply partners.
• The company and its ODM/OEM and packaging supply partners are susceptible to supply shortages and interruptions, long lead times, and price fluctuations for raw materials and ingredients.
• The company is subject to complex and evolving product safety laws, regulations and standards.
• The company may be subject to export and import control laws and regulations.
• The company is subject to fluctuations in exchange rates in the MYR.
• The company may be subject to infringement claims of intellectual property rights or other rights of third parties.
• The company is controlled by a single shareholder, whose interest in the business may be different than yours.

Future Outlook

The company intends to use the proceeds from the offering for working capital, market penetration and development, operating expenses, and transaction expenses. The company plans to expand its product offerings, enter new markets, and invest in new technologies.

Management Comments

• Under the leadership of our founder, Prof. Dr. Yeoh Chee Wei, our company has steadily and successfully transcended its humble origins in the beauty industry during an operating history that spans nearly two decades.
• Our accomplishments reflect a commitment to providing safe, professional-grade products of uncompromising quality.
• We take pride in our ability to adapt and respond swiftly to dynamic market needs, positioning our company as a versatile and forward-thinking enterprise.

Industry Context

The announcement comes amid a growing global beauty market and a recovering healthcare market post-COVID-19, with the company strategically positioning itself to capitalize on these trends. The company is also expanding its product offerings to include cosmetics and skincare in these regions.

Comparison to Industry Standards

• The company's revenue decline in 2023 reflects a broader trend in the healthcare sector as demand for pandemic-related products decreased.
• The company's focus on expanding its beauty segment aligns with the industry's growth in the Asia-Pacific region.
• The company's reliance on a limited number of suppliers is a common practice in the industry, but it also presents a risk.
• The company's commitment to product safety and compliance with regulations is consistent with industry standards.
• The company's expansion into new markets and territories is a common strategy for growth in the beauty and healthcare industries.

Related Party Transactions

• The company has an Exclusive Sole Distribution Agreement with Jingga Anggun Sdn Bhd, a company where the son of the CEO is the sole director and the COO is also the COO of Jingga Anggun.
• The company has an agreement with Mosfac Sdn Bhd, a company where the CEO is a 50% shareholder and a director.
• The company has outstanding receivables from Mimo Motor Sdn Bhd, a company where the CEO is the sole shareholder and a director.

Stakeholder Impact

• Shareholders will have the opportunity to invest in a company with a long history and growth potential.
• Employees may benefit from the company's expansion and growth.
• Customers will have access to a wider range of products and services.
• Suppliers will have the opportunity to expand their business with the company.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• The company will proceed with the IPO process, including listing its shares on the Nasdaq Capital Market.
• The company will use the proceeds from the offering for working capital, market penetration and development, operating expenses, and transaction expenses.
• The company will continue to expand its product offerings, enter new markets, and invest in new technologies.

Key Dates

Keywords

IPO, Nasdaq, beauty, healthcare, eyebrow pencils, face masks, skincare, ASEAN, Malaysia, EMPRO, cosmetics, medical devices